Suraksha Q2 FY27 PAT rises 69% as EBITDA margin reaches 36.7%
Key highlights
- Suraksha reported Q2 FY27 PAT of Rs 14.95 crore, up 69.34% year-on-year.
- Suraksha's Q2 FY27 EBITDA margin increased to 36.7% from 31.7% in Q2 FY26.
- Suraksha served 0.42 million patients and performed 2.40 million tests in Q2 FY27.
- Suraksha ended Q2 FY27 with 77 centres, versus 63 centres in Q2 FY26.
powered by IRIS

Suraksha Diagnostic Limited reported Q2 FY27 profit after tax of Rs 14.95 crore, up 69% year-on-year, while earnings before interest, tax, depreciation and amortisation (EBITDA) margin rose to 36.7% from 31.7%. Total revenue increased 26% to Rs 100.575 crore, with higher patient and test volumes and improving contribution from recently commissioned centres cited by management.
Know Suraksha Diagnostic inside out
Results, valuation, peers and who's buying, in one view.
How did Suraksha perform in Q2 FY27?
Suraksha increased Q2 FY27 total revenue by 26.38% year-on-year to Rs 100.575 crore, EBITDA by 45.47% to Rs 36.317 crore and profit after tax (PAT) by 69.34% to Rs 14.95 crore. The gap between revenue and profit growth coincided with a 500-basis-point expansion in EBITDA margin and a 390-basis-point rise in PAT margin to 15.1% from 11.2%. A basis point is one-hundredth of a percentage point.
Sequentially, Q2 FY27 total revenue rose 13.35% from Rs 88.733 crore in Q1 FY27, while EBITDA rose 15.18% from Rs 31.530 crore and PAT increased 16.39% from Rs 12.845 crore. Profit before tax was Rs 18.872 crore, 56.65% higher than Rs 12.047 crore in Q2 FY26, and no exceptional item was recorded in either period.
Why did Suraksha's profit grow faster than revenue?
Suraksha's EBITDA margin reached 36.7% in Q2 FY27, compared with 31.7% a year earlier and 36.0% in Q1 FY27, so EBITDA growth of 45.47% exceeded the 26.38% increase in total revenue. The PAT margin also rose to 15.1% from 11.2% in Q2 FY26, contributing to PAT growth of 69.34%.
The cost base increased in absolute terms as revenue expanded: material consumption was Rs 11.248 crore, employee-benefit expense was Rs 14.959 crore and other expenses were Rs 38.143 crore in Q2 FY27. EBITDA increased by Rs 11.351 crore from Rs 24.966 crore in Q2 FY26, while total revenue increased by Rs 20.995 crore, resulting in the reported margin expansion.
Management attributed the quarterly performance to growth in patient and test volumes and an improving contribution from centres commissioned in recent quarters. Depreciation and amortisation was Rs 12.607 crore and finance cost was Rs 4.838 crore in Q2 FY27, versus Rs 10.143 crore and Rs 2.776 crore respectively a year earlier, while operating earnings rose faster than these expenses.
What operating metrics supported Suraksha's Q2 FY27 revenue?
Suraksha served 0.42 million patients and performed 2.40 million tests in Q2 FY27, compared with 0.38 million patients and 2.20 million tests in Q2 FY26. Revenue per patient rose to Rs 2,348 from Rs 2,083, while EBITDA per patient increased to Rs 861 from Rs 661.
The patient count was also higher than the 0.38 million reported in Q1 FY27, while tests increased from 2.10 million in that quarter to 2.40 million. Revenue per patient increased by Rs 27 sequentially from Rs 2,321, and EBITDA per patient increased by Rs 26 from Rs 835, alongside the increase in quarterly EBITDA margin to 36.7%.
Suraksha ended Q2 FY27 with 77 centres, up from 63 in Q2 FY26 and 72 in Q1 FY27. Management said it commissioned five centres during the quarter, comprising two hub centres and three spoke centres, as part of its cluster-building and network-density approach.
Got a follow-up? Ask IRIS
How are newer centres contributing to Suraksha's margins?
Suraksha reported that centres more than two years old had a Q2 FY27 EBITDA margin of 42.0%, compared with 40.9% in Q1 FY27. Centres less than two years old reported an 11.8% margin, up from 6.5% in Q1 FY27 and negative 16.8% in Q2 FY26.
The improvement at younger centres coincided with the overall EBITDA margin increasing from 31.7% in Q2 FY26 to 36.7% in Q2 FY27. The presentation identifies 45 centres more than two years old and 32 centres less than two years old using age brackets stated as of March 31, 2026, compared with 42 and 26 centres respectively under brackets stated as of June 30, 2025.
Management said the contribution from centres commissioned over the past few quarters was improving, but it did not quantify their revenue or EBITDA contribution. The disclosed margin pattern shows that newer centres remained below the 42.0% margin of mature centres in Q2 FY27, even as their margin improved by 2,860 basis points from negative 16.8% in Q2 FY26.
What does H1 FY27 show about Suraksha's expansion and cash generation?
Suraksha reported H1 FY27 total revenue of Rs 189.309 crore, up 23.67% from Rs 153.072 crore in H1 FY26, while EBITDA grew 36.73% to Rs 67.847 crore and PAT grew 54.39% to Rs 27.796 crore. H1 EBITDA margin rose to 36.3% from 32.8%, and PAT margin increased to 14.9% from 11.9%.
H1 FY27 patient footfall increased to 0.80 million from 0.71 million and tests performed rose to 4.50 million from 4.13 million. Revenue per patient increased to Rs 2,335 from Rs 2,120, while EBITDA per patient increased to Rs 849 from Rs 695; the centre network expanded by 14 locations to 77.
Net cash from operating activities was Rs 58.794 crore in H1 FY27, compared with Rs 36.693 crore in H1 FY26, while purchases of property, plant and equipment and other intangible assets were Rs 33.591 crore. Cash flow from investing activities was an outflow of Rs 47.570 crore, including Rs 15.965 crore invested in bank deposits, and closing cash and cash equivalents were Rs 5.669 crore.
Conclusion
Suraksha's Q2 FY27 results combined 26.38% total-revenue growth with a 500-basis-point year-on-year increase in EBITDA margin, resulting in 69.34% PAT growth to Rs 14.95 crore. Higher revenue and EBITDA per patient, a patient count of 0.42 million, and the improving 11.8% margin at centres less than two years old were the disclosed operating features behind the result.
The next disclosed execution markers are the contribution of maturing centres and FY27 expansion plans. Suraksha had launched three hubs and six spokes by the presentation date and listed four hubs and seven spokes as upcoming across Greater Kolkata, Rest of Bengal, Jharkhand, Tripura, Assam and Bihar; management said it remains focused on disciplined expansion in the second half of FY27.


